Suppr超能文献

医疗服务提供者对辅助内分泌治疗相关症状管理的障碍和促进因素的看法。

Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.

作者信息

Samuel Cleo A, Turner Kea, Donovan Heidi A S, Beckjord Ellen, Cardy Alexandra, Dew Mary Amanda, van Londen G J

机构信息

Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 1105F McGavran-Greenberg Hall, CB# 7411, Chapel Hill, NC, 27599-7411, USA.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC, USA.

出版信息

Support Care Cancer. 2017 Dec;25(12):3723-3731. doi: 10.1007/s00520-017-3799-0. Epub 2017 Jul 6.

Abstract

PURPOSE

Adjuvant endocrine therapy (AET) utilization is linked to improved clinical outcomes among breast cancer survivors (BCS); yet, AET adherence rates remain suboptimal. Little is known about provider perspectives regarding barriers and facilitators to AET-related symptom management (SM). In this study, we examined provider perspectives on the barriers and facilitators to AET-related SM among BCS and opportunities for improvement.

METHODS

We conducted three focus groups (FGs) with a multidisciplinary group of healthcare providers (n = 13) experienced in caring for BCS undergoing AET. We utilized semi-structured discussion guides to elicit provider perspectives on AET-related SM. FGs were audiotaped, transcribed, and analyzed using qualitative software to identify key themes.

RESULTS

Providers described patient-, provider-, and system-level barriers and facilitators to AET-related SM. At the patient-level, barriers included competing demands, limited time/resources, and possible misattribution of some symptoms to AET, while family/social relationships and insurance emerged as important facilitators. Discomfort with SM, limited time, and challenges distinguishing AET-related symptoms from other conditions were key provider-level barriers. Provider-level facilitators included routine symptom documentation and strong provider relationships. Care fragmentation and complexity of the cancer care delivery system were described as system-level barriers; however, survivor clinics were endorsed by providers.

CONCLUSIONS

Provider perspectives on AET-related SM can shed light on SM barriers and facilitators spanning multiple levels of the cancer care delivery system. Strategies for improving AET-related SM in BCS include increasing patients' knowledge and engagement in SM, equipping providers with efficient SM strategies, and improving coordination of symptom-related services through survivorship programs.

摘要

目的

辅助内分泌治疗(AET)的应用与乳腺癌幸存者(BCS)临床结局的改善相关;然而,AET的依从率仍不尽人意。关于医疗服务提供者对AET相关症状管理(SM)的障碍和促进因素的看法,我们知之甚少。在本研究中,我们考察了医疗服务提供者对BCS中AET相关SM的障碍和促进因素以及改进机会的看法。

方法

我们与一组多学科的医疗服务提供者(n = 13)进行了三次焦点小组讨论(FGs),这些提供者在照顾接受AET的BCS方面经验丰富。我们使用半结构化讨论指南来引出医疗服务提供者对AET相关SM的看法。FGs进行了录音、转录,并使用定性软件进行分析以确定关键主题。

结果

医疗服务提供者描述了AET相关SM在患者、医疗服务提供者和系统层面的障碍和促进因素。在患者层面,障碍包括相互竞争的需求、有限的时间/资源,以及一些症状可能被错误归因于AET,而家庭/社会关系和保险则成为重要的促进因素。对SM的不适、时间有限以及难以将AET相关症状与其他病症区分开来是医疗服务提供者层面的关键障碍。医疗服务提供者层面的促进因素包括常规症状记录和良好的医患关系。癌症护理提供系统的护理碎片化和复杂性被描述为系统层面的障碍;然而,幸存者诊所得到了医疗服务提供者的认可。

结论

医疗服务提供者对AET相关SM的看法有助于揭示癌症护理提供系统多个层面的SM障碍和促进因素。改善BCS中AET相关SM的策略包括增加患者对SM的了解和参与度,为医疗服务提供者配备有效的SM策略,以及通过幸存者计划改善症状相关服务的协调。

相似文献

1
Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.
Support Care Cancer. 2017 Dec;25(12):3723-3731. doi: 10.1007/s00520-017-3799-0. Epub 2017 Jul 6.
2
Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management.
Support Care Cancer. 2017 Apr;25(4):1055-1061. doi: 10.1007/s00520-016-3491-9. Epub 2016 Nov 18.
3
Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.
Oncol Nurs Forum. 2014 Nov 1;41(6):660-8. doi: 10.1188/14.ONF.660-668.
4
Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
BMC Cancer. 2018 Jul 11;18(1):732. doi: 10.1186/s12885-018-4644-7.
5
Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
Curr Oncol. 2021 Apr 9;28(2):1472-1482. doi: 10.3390/curroncol28020139.
8
Facilitators of Survivorship Care Among Underserved Breast Cancer Survivors: a Qualitative Study.
J Cancer Educ. 2017 Dec;32(4):756-763. doi: 10.1007/s13187-016-1064-8.
9
Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Breast Cancer Res Treat. 2018 Feb;167(3):615-633. doi: 10.1007/s10549-017-4561-5. Epub 2017 Nov 6.
10
Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
Eur J Oncol Nurs. 2020 Feb;44:101706. doi: 10.1016/j.ejon.2019.101706. Epub 2019 Nov 30.

本文引用的文献

1
Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management.
Support Care Cancer. 2017 Apr;25(4):1055-1061. doi: 10.1007/s00520-016-3491-9. Epub 2016 Nov 18.
2
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Breast. 2015 Oct;24(5):630-6. doi: 10.1016/j.breast.2015.06.010. Epub 2015 Jul 16.
3
Adjuvant therapy use among Appalachian breast cancer survivors.
Medicine (Baltimore). 2015 Jul;94(26):e1071. doi: 10.1097/MD.0000000000001071.
6
Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.
Oncol Nurs Forum. 2014 Nov 1;41(6):660-8. doi: 10.1188/14.ONF.660-668.
7
American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning.
J Oncol Pract. 2014 Nov;10(6):345-51. doi: 10.1200/JOP.2014.001321. Epub 2014 Oct 14.
10
Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer.
Oncol Nurs Forum. 2014 May;41(3):274-85. doi: 10.1188/14.ONF.274-285.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验